The cardioprotective effects of GLP-1 receptor agonists in patients with type 2 diabetes — including novel findings for reduced stroke — are consistent across the drug class, a major review has shown.

Results from the largest pooled study on the agents to date also suggest the cardiovascular benefits are not confined to the human-based incretin mimetics but also extend to the older exendin-4-based drugs, the UK-led researchers say.